ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.
Although the PD-1/PD-L1 market is rapidly becoming saturated, with several drugs already approved and many more candidates undergoing clinical trials, ImmuneOncia Therapeutics, Inc. is challenging the space by targeting rare cancers of less interest to global big pharma firms, as well as cancers that have specific molecular signatures.
“This market is crowded. Still, there are two ways to get approvals for indications. We are confident that we can...
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.
